检查点阻断通过支持共刺激调节T细胞命运。

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-12-16 DOI:10.1038/s43018-024-00871-5

{"title":"检查点阻断通过支持共刺激调节T细胞命运。","authors":"","doi":"10.1038/s43018-024-00871-5","DOIUrl":null,"url":null,"abstract":"By tracking the fate of tumor-specific T cells mobilized in lymph nodes by dual blockade of PD-1 and TIGIT, we show that both exhausted T cells and effector T cells can emerge from a common progenitor. Signaling by the co-stimulatory receptors CD28 and CD226 is important for deciding between these two cell fates.","PeriodicalId":18885,"journal":{"name":"Nature cancer","volume":"5 12","pages":"1796-1797"},"PeriodicalIF":23.5000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Checkpoint blockade regulates T cell fate by supporting co-stimulation\",\"authors\":\"\",\"doi\":\"10.1038/s43018-024-00871-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"By tracking the fate of tumor-specific T cells mobilized in lymph nodes by dual blockade of PD-1 and TIGIT, we show that both exhausted T cells and effector T cells can emerge from a common progenitor. Signaling by the co-stimulatory receptors CD28 and CD226 is important for deciding between these two cell fates.\",\"PeriodicalId\":18885,\"journal\":{\"name\":\"Nature cancer\",\"volume\":\"5 12\",\"pages\":\"1796-1797\"},\"PeriodicalIF\":23.5000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s43018-024-00871-5\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cancer","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s43018-024-00871-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

通过追踪PD-1和TIGIT双重阻断在淋巴结中动员的肿瘤特异性T细胞的命运，我们发现耗竭T细胞和效应T细胞都可以从一个共同的祖细胞中出现。由共刺激受体CD28和CD226发出的信号对于决定这两种细胞命运非常重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Checkpoint blockade regulates T cell fate by supporting co-stimulation

查看原文本刊更多论文

Checkpoint blockade regulates T cell fate by supporting co-stimulation

By tracking the fate of tumor-specific T cells mobilized in lymph nodes by dual blockade of PD-1 and TIGIT, we show that both exhausted T cells and effector T cells can emerge from a common progenitor. Signaling by the co-stimulatory receptors CD28 and CD226 is important for deciding between these two cell fates.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.